AARD Aardvark Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1774857 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.2%
TTM EPS YoY22.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-80.9%
ROA-73.5%
ROIC (approx.)-149.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets11.1%
Debt / equity0.00x
Current ratio9.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| R&D expense | $15.67M | $10.46M | $16.57M | $14.30M | $13.74M | $13.14M | $7.75M | $8.06M |
| SG&A expense | $4.05M | $4.63M | $5.90M | $4.41M | $3.97M | $2.70M | $2.71M | $1.39M |
| Operating income | -$19.72M | -$15.08M | -$22.46M | -$18.70M | -$17.70M | -$15.85M | -$10.47M | -$9.45M |
| Net income | -$19.19M | -$14.39M | -$21.59M | -$17.60M | -$16.32M | -$14.37M | -$9.31M | -$8.78M |
| EBITDA | -$19.71M | -$15.07M | -$22.45M | -$18.69M | -$17.69M | -$15.84M | -$10.46M | -$9.44M |
| EPS (basic) | -0.88 | -0.66 | -0.99 | — | -0.75 | -0.66 | -0.71 | — |
| EPS (diluted) | -0.88 | -0.66 | -0.99 | — | -0.75 | -0.66 | -0.71 | — |
| Weighted avg. shares (diluted) | 21.89M | 21.85M | 21.82M | — | 21.71M | 21.69M | 13.19M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $60.34M | $73.85M | $62.44M | $47.05M | $39.28M | $26.00M | $26.50M | $61.64M |
| Short-term investments | $13,000 | $21,000 | $28.76M | $62.98M | $87.06M | $115.82M | $124.76M | $12.02M |
| Current assets | $64.11M | $80.66M | $93.58M | $111.89M | $129.21M | $144.77M | $154.55M | $74.14M |
| Total assets | $64.80M | $81.46M | $98.59M | $117.18M | $133.23M | $147.47M | $157.03M | $77.51M |
| Current liabilities | $7.03M | $6.39M | $11.60M | $10.55M | $10.74M | $10.31M | $5.98M | $4.93M |
| Total liabilities | $7.19M | $6.66M | $11.60M | $10.55M | $10.85M | $10.55M | $6.34M | $5.39M |
| Shareholders' equity | $57.61M | $74.80M | $86.99M | $106.63M | $122.38M | $136.93M | $150.69M | -$54.64M |
| Shares outstanding | 21.89M | 21.88M | 21.82M | 21.82M | 21.75M | 21.69M | 21.69M | 4.07M |
| Cash flow statement | ||||||||
| Operating cash flow | -$13.54M | -$17.60M | -$18.87M | -$16.81M | -$16.13M | -$9.84M | -$11.39M | -$7.73M |
| Capital expenditure | $0 | — | — | $0 | $4,000 | $91,000 | $0 | $6,000 |
| Free cash flow | -$13.54M | — | — | -$16.81M | -$16.13M | -$9.94M | -$11.39M | -$7.73M |
| Investing cash flow | $0 | $28.75M | $34.25M | $24.30M | $29.25M | $9.41M | -$112.62M | -$11.89M |
| Financing cash flow | $22,000 | $262,000 | $4,000 | $274,000 | $171,000 | -$71,000 | $88.88M | -$1.01M |
| Depreciation & amortization | $10,000 | $11,000 | $11,000 | $10,000 | $10,000 | $11,000 | $5,000 | $8,000 |
| Stock-based compensation | $1.97M | $1.95M | $2.00M | $1.58M | $1.50M | $634,000 | $233,000 | $173,000 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.